What changed
Biogen delivered a strong beat with Non-GAAP diluted EPS of $2.62 versus the $1.98 consensus, a $0.64 beat (+32.5%). Total revenue came in at $2,804M, up 10.6% YoY, driven by Growth Portfolio strength including the first full quarter contribution from acquired Apellis products. FY2026 Non-GAAP diluted EPS guidance was raised at the lower end to $12.20-$13.00 from $12.00-$13.00, reflecting ongoing business strength and Apellis dilution favorability.
Why it matters
Biogen delivered a strong beat with Non-GAAP diluted EPS of $2.62 versus the $1.98 consensus, a $0.64 beat (+32.5%). Total revenue came in at $2,804M, up 10.6% YoY, driven by Growth Portfolio strength